Welcome to our dedicated page for Plexus SEC filings (Ticker: PLXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Plexus Corp.'s SEC filings document operating results, financial condition, governance matters and material corporate events for its complex product design, manufacturing and services business. Recent 8-K reports furnish quarterly and fiscal-year earnings releases and related financial information for the company's product lifecycle operations across regulated end markets.
The filings also record shareholder meeting results, including director elections, advisory executive compensation votes and auditor ratification, as well as officer transition and compensation-arrangement disclosures. These records describe formal governance actions, executive roles and recurring public-company reporting obligations for PLXS.
Plexus Corp. filed its Annual Report (10-K) for the fiscal year ended September 27, 2025. The company designs, manufactures and services highly complex products across Aerospace/Defense, Healthcare/Life Sciences, and Industrial markets, operating 26 facilities with a global team of over 20,000. Management targets long-term compounded annual revenue growth of 9–12% and a 15% ROIC; Plexus’ internal WACC for fiscal 2025 was 8.9%.
Customer exposure is diversified: approximately 190 customers in fiscal 2025 and no single customer over 10% of sales. Net sales mix in 2025 was 17% Aerospace/Defense, 40% Healthcare/Life Sciences, and 43% Industrial. Shares outstanding were 27,121,994 as of March 29, 2025; as of November 10, 2025, there were 26,774,415 shares outstanding. The company highlights robust certifications (including ISO and FDA-related capabilities) and details risk factors such as supply chain constraints, regulatory complexity, competition, and geopolitical volatility.
Plexus Corp (PLXS) Executive VP & CFO reported insider transactions. On 11/11/2025, he sold 2,000 shares of common stock at $143.535. On 11/12/2025, 6,458 Performance Stock Units (PSUs) were converted to common stock (code M), and 3,036 shares were withheld to cover taxes at $146.24 (code F).
After these transactions, he held 20,383 shares directly and 3,719 shares in the company 401(k). The filing notes that, based on company performance for economic return goals over three years, 138% of the fiscal 2023 PSU tranche vested; the relative TSR portion’s performance period has not concluded.
Plexus Corp (PLXS) reported an insider transaction by its Exec VP, CAO, General Counsel & Secretary. On 11/10/2025, the officer sold 2,500 shares of common stock, coded “S” for sale, at a weighted average price of $145.2771. Following the sale, the reporting person beneficially owns 20,895 shares, held directly.
The filing notes the sale was executed in multiple trades within a price range of $145.0001 to $145.56 per share, with the weighted average reported. This is a routine Form 4 disclosure of insider activity and does not alter the company’s capital structure.
Plexus Corp. (PLXS) director reported a personal stock transaction. On 11/04/2025, the reporting person made a bona fide gift of 700 shares of Plexus common stock, coded “G.” After this transaction, the reporting person beneficially owns 8,165 shares, held directly.
This filing reflects a charitable or personal transfer and does not indicate a sale for proceeds.
Plexus Corp (PLXS) President & CEO and director Todd P. Kelsey reported open‑market sales of common stock on 11/03/2025, 11/04/2025, and 11/05/2025 pursuant to a Rule 10b5‑1 plan adopted on August 16, 2024. He sold 1,500 shares at $139.12, 2,000 shares at $143.50, and 2,000 shares at $145.10. After these transactions, he beneficially owned 58,714 shares, held directly.
Plexus Corp (PLXS) reported an amended insider filing. A company director filed a Form 4/A to correct the reported equity award to 1,370 Restricted Stock Units granted on 02/03/2025. Each RSU represents a right to receive one share of Plexus common stock under the 2024 Omnibus Incentive Plan. The RSUs vest on February 3, 2026, and the filing lists direct ownership. The amendment states it was filed to correct the number of RSUs granted.
Plexus Corp (PLXS) reported an insider update. Director Michael V. Schrock filed a Form 4/A amending a prior report to reflect the acquisition of 1,370 restricted stock units on February 3, 2025 under the Plexus Corp. 2024 Omnibus Incentive Plan.
Each RSU represents the right to receive one share of Plexus common stock. The RSUs vest on February 3, 2026. The amendment states it was filed to correct the number of Restricted Stock Units granted.
Plexus Corp (PLXS) reported an amended insider filing. A company director filed a Form 4/A to correct the size of a previously reported equity award to 1,370 Restricted Stock Units granted on 02/03/2025 under the Plexus Corp. 2024 Omnibus Incentive Plan, reported with transaction code A.
Each RSU represents a contingent right to receive one share of Plexus common stock and vests on 02/03/2026. Following the transaction, 1,370 derivative securities were beneficially owned directly. The amendment notes the change was made to correct the number of RSUs granted.
Plexus Corp (PLXS) reported a Form 4/A by Director Karen Rapp amending a prior filing to correct the size of a restricted stock unit grant. On February 3, 2025, 1,370 Restricted Stock Units were awarded under the Plexus Corp. 2024 Omnibus Incentive Plan, which qualifies under Rule 16b-3. Each RSU represents one share of common stock and vests on February 3, 2026. Following the transaction, 1,370 derivative securities were beneficially owned directly.
Plexus Corp (PLXS) disclosed an amended Form 4 for director J. Joel Quadracci, reporting the acquisition of 1,370 Restricted Stock Units on 02/03/2025 under the Plexus Corp. 2024 Omnibus Incentive Plan.
Each RSU represents a contingent right to receive one share of Plexus common stock, and the RSUs vest on 02/03/2026. Following the reported transaction, the filing lists 1,370 derivative securities beneficially owned, held directly. The amendment states it was filed to correct the number of RSUs granted.